Location Directory

Clinical trials in Phoenix, Arizona

This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8144

Shown on this page

Current sort

Institutions in Phoenix

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Agitation, Alzheimer Disease
Interventions: BMS-986368, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 60
States / cities: Homewood, Alabama • Huntsville, Alabama • Phoenix, Arizona + 52 more

Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer With Bone Involvement, Bone Metastases in Subjects With Advanced Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Hormone-Sensitive Breast Cancer
Interventions: RYZ101, Standard of Care Endocrine Therapy; Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: Not listed
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 25
States / cities: Phoenix, Arizona • Irvine, California • San Diego, California + 21 more

Conditions: Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Liposarcoma
Interventions: Silmitasertib, Irinotecan, Temozolomide, Vincristine; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Up to 30 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 20 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib; Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 60 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 88
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 76 more

Conditions: Early Alzheimer's Disease
Interventions: Lecanemab IV, Placebo, Lecanemab SC; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1,906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 112
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 82 more

Conditions: Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions: Radiation Therapy, Temozolomide, Veliparib; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 25 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 145
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more

Conditions: Atopic Dermatitis
Interventions: Tilrekimig, Dupilumab, Placebo for Tilrekimig, Placebo for Dupilumab; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 1,375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Phoenix, Arizona • Huntington Beach, California • Northridge, California + 9 more

Conditions: Cardiovascular Risk, Obesity
Interventions: Zenagamtide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 45 Years and older
Enrollment: 8,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 155
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 134 more

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions: Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration, Trametinib dimethyl sulfoxide; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 199
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more

Conditions: Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, External Beam Radiation Therapy, Ganitumab, Ifosfamide, Stereotactic Radiosurgery, Therapeutic Surgical Procedure, Vincristine, Vincristine Sulfate; Drug · Radiation · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 50 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 298
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 203 more

Conditions: Tricuspid Regurgitation (TR)
Interventions: Tricuspid Transcatheter Edge-to-Edge Repair (TEER); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 5
States / cities: Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 2 more

Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Interventions: Emavusertib, Ibrutinib; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more

Clinical trials in Phoenix, Arizona

Filter and sort this location

Institutions in Phoenix

Live official records

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

A Post-Market Assessment of the Safety and Performance of the TriClip™ System

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)